Data has been provided by market participants, and regions (North America, Asia Pacific, Europe, Middle East & Africa, and South America)
FEBS Open Bio 10 (4), 637643
In a nutshell People with type 2 diabetes taking semaglutide (Ozempic/Wegovy) showed up to 46% lower dementia risk compared to those on other diabetes medications The protective effects were strongest in younger adults under 65, women, and patients with obesity While promising, this observational study cant prove the drug prevents dementiamore research through clinical trials is needed CLEVELAND For millions of Americans taking Ozempic or Wegovy, there might be more good news coming
In this environment, trust must be actively earned through verification rather than passively assumed
"The benefits seem to outweigh the risks when you have moderate to severe obesity," Dr
In a multicenter, randomized, placebo-controlled dose-finding trial, cagrilintide at doses ranging from 0.3 to 4.5 mg weekly produced dose-dependent weight reductions, with the 4.5 mg dose achieving approximately 10.8% weight loss at 26 weeks compared to 3.0% with placebo
